NEW YORK (GenomeWeb News) – Epigenetics-based cancer test developer PrognosDx has named Joseph Vallner to be its new CEO. Vallner, who formerly was president and COO at Cell Genesys, will succeed founding President and CEO Kamran Tahamtanzadeh, who will continue to serve as chairman of the board of directors.

The company is preparing to launch its PrognoScore test to predict clinical outcomes and assess risk probabilities for prostate cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.